Cancer Research and Treatment

Original Articles

Poor Preoperative Glycemic Control Is Associated with Dismal Prognosis after Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Korean Multicenter Study: Sung Gu Kang, Eu Chang Hwang, Seung Il Jung, Ho Song Yu, Ho Seok Chung, Taek Won Kang, Dong Deuk Kwon, Jun Eul Hwang, Jun Seok Kim, Joon Hwa Noh, Jae Hyung You, Myung Ki Kim, Tae Hoon Oh, Ill Young Seo, Seung Baik, Chul-Sung Kim, Seok Ho Kang, Jun Cheon; Cancer Res Treat. 2016;48(4):1293-1301. Published online March 23, 2016; DOI: https://doi.org/10.4143/crt.2016.021

Purpose
The purpose of this study is to evaluate the effect of diabetes mellitus (DM) and preoperative glycemic control on prognosis in Korean patients with upper tract urothelial carcinoma (UTUC) who underwent radical nephroureterectomy (RNU). Materials and Methods A total of 566 patients who underwent RNU at six institutions between 2004 and 2014 were reviewed retrospectively. Kaplan-Meier and Cox regression analyses were performed to assess the association between DM, preoperative glycemic control, and recurrence-free, cancer-specific, and overall survival.
Results
The median follow-up period was 33.8 months (interquartile range, 41.4 months). A total of 135 patients (23.8%) had DM and 67 patients (11.8%) had poor preoperative glycemic control. Patients with poor preoperative glycemic control had significantly shorter median recurrence-free, cancer-specific, and overall survival than patients with good preoperative glycemic control and non-diabetics (all, p=0.001). In multivariable Cox regression analysis, DM with poor preoperative glycemic control showed association with worse recurrence-free survival (hazard ratio [HR], 2.26; 95% confidence interval [CI], 1.31 to 3.90; p=0.003), cancer-specific survival (HR, 2.96; 95% CI, 1.80 to 4.87; p=0.001), and overall survival (HR, 2.13; 95% CI, 1.40 to 3.22; p=0.001). Conclusion Diabetic UTUC patients with poor preoperative glycemic control had significantly worse oncologic outcomes than diabetic UTUC patients with good preoperative glycemic control and non-diabetics. Further investigation is needed to elucidate the exact mechanism underlying the impact of glycemic control on UTUC treatment outcome.

Citations

Citations to this article as recorded by

Development and validation of a prediction model for early recurrence in upper tract urothelial carcinoma treated with radical nephroureterectomy
Yi-Ju Chou, Hao-Lun Luo, Hung-Jen Wang, Steven K. Huang, Yu-Che Hsieh, Wen-Jeng Wu, Ching-Chia Li, Han-Yu Weng, Ta-Yao Tai, Chao-Hsiang Chang, Hsi-Chin Wu, Po-Hung Lin, Jacob See-Tong Pang, Chung-Hsin Chen, Jian-Hua Hong, Jen-Shu Tseng, Marcelo Chen, I-Hs
BMC Cancer.2025;[Epub] CrossRef
Identifying ways to improve diabetes management during cancer treatments (INDICATE): protocol for a qualitative interview study with patients and clinicians
Laura Ashley, Saifuddin Kassim, Ian Kellar, Lisa Kidd, Frances Mair, Mike Matthews, Mollie Price, Daniel Swinson, Johanna Taylor, Galina Velikova, Jonathan Wadsley
BMJ Open.2022; 12(2): e060402. CrossRef
Annular-shaped stenosis in the ureter: Caution should be taken
Jie Ming, Yue Wang, Ziliang Su, Chunyang Wang
Urologic Oncology: Seminars and Original Investigations.2022; 40(6): 274.e7. CrossRef
Glycosylated haemoglobin and prognosis in 10,536 people with cancer and pre-existing diabetes: a meta-analysis with dose-response analysis
Suping Ling, Michael Sweeting, Francesco Zaccardi, David Adlam, Umesh T. Kadam
BMC Cancer.2022;[Epub] CrossRef
Malnutrition management of hospitalized patients with diabetes/hyperglycemia and cancer cachexia
Rosa Burgos Peláez, José Pablo Suárez Llanos, Jose Manuel García Almeida, Pilar Matía Martín, Samara Palma Milla, Alejandro Sanz Paris, Ana Zugasti Murillo, Ana Artero-Fullana, Alfonso Calañas Continente, M.ª Jesús Chinchetru, Katherine García Malpartida,
Nutrición Hospitalaria.2022;[Epub] CrossRef
The Impact of Diabetes on the Prognosis of Upper Tract Urothelial Carcinoma After Radical Nephroureterectomy: A Systematic Review and Meta-Analysis
Xiaoshuai Gao, Liang Zhou, Jianzhong Ai, Wei Wang, Xingpeng Di, Liao Peng, Banghua Liao, Xi Jin, Hong Li, Kunjie Wang
Frontiers in Oncology.2021;[Epub] CrossRef
The Prognostic Value of Lymphovascular Invasion in Patients With Upper Tract Urinary Carcinoma After Surgery: An Updated Systematic Review and Meta-Analysis
Lijin Zhang, Bin Wu, Zhenlei Zha, Hu Zhao, Jun Yuan, Yejun Feng
Frontiers in Oncology.2020;[Epub] CrossRef
The impact of preoperative glycated hemoglobin levels on outcomes in oral squamous cell carcinoma
Ze Yun Tay, Huang‐Kai Kao, Kuang‐Hsu Lien, Shao‐Yu Hung, Yenlin Huang, Ngan‐Ming Tsang, Kai‐Ping Chang
Oral Diseases.2020; 26(7): 1449. CrossRef

11,065 View
121 Download
9 Web of Science
8 Crossref

CD10 Is Again Expressed at a Certain Stage during the Neoplastic Process of Bladder Transitional Cell Carcinomas: Tae Jung Jang; Cancer Res Treat. 2012;44(4):262-266. Published online December 31, 2012; DOI: https://doi.org/10.4143/crt.2012.44.4.262

Abstract PDF PubReader ePub

PURPOSE
CD10, a membrane-bound zinc-dependent metallopeptidase, is normally expressed in many tissues. Accordingly, the derangement of CD10 expression may be related to development or progression in a variety of tumors. The aim of this study is to examine any association between CD10 expression and clinicopathological parameters in bladder transitional cell carcinomas (TCCs) and the relationship between expression of E-cadherin and CD10.
MATERIALS AND METHODS
Immunohistochemical staining was performed for CD10 and E-cadherin in tissues of 94 TCCs and 10 non-neoplastic bladder mucosa.
RESULTS
Positive immunoreactivity for CD10 was observed in non-neoplastic urothelium at a proportion of 80% and TCCs were observed at a rate of 23%. A positive rate of CD10 expression was observed in 10% of total cases of a low grade tumor and in 35% of those of a high grade tumor. It was also observed in 15% of pTa tumors, 13% of pT1 tumors, and 48% of pT2 tumors. In addition, CD10 expression showed reciprocal correlation with expression of membranous E-cadherin in tumors.
CONCLUSION
CD10 is again expressed at a certain stage during the neoplastic process of TCCs and could play some roles intheir carcinogenesis.

Citations

Citations to this article as recorded by

Expression of CD10 in urothelial carcinoma of the bladder and its correlation with histopathological grade, pathological stage, and survival of patients
Sushil Kumar Shukla, Smita Chandra, Neena Chauhan, Rajeev Sarpal
Journal of Cancer Research and Therapeutics.2021; 17(4): 887. CrossRef
Overexpression of membrane metalloendopeptidase inhibits substance P stimulation of cholangiocarcinoma growth
Fanyin Meng, Sharon DeMorrow, Julie Venter, Gabriel Frampton, Yuyan Han, Heather Francis, Holly Standeford, Shanika Avila, Kelly McDaniel, Matthew McMillin, Syeda Afroze, Micheleine Guerrier, Morgan Quezada, Debolina Ray, Lindsey Kennedy, Laura Hargrove,
American Journal of Physiology-Gastrointestinal and Liver Physiology.2014; 306(9): G759. CrossRef

10,440 View
67 Download
2 Crossref

Results of Additional BCG Therapy for Recurrent Transitional Cell Carcinoma after Complete Response to Initial BCG Therapy: H S Ha, C H Park, C I Kim; J Korean Cancer Assoc. 2000;32(2):367-373.

Abstract PDF: PURPOSE
The effect of repeated 6 week courses of intravesical BCG therapy after early failure of the first induction course is well known, but few studies have evaluated the effect of repeat BCG therapy for transitional cell carcinoma (TCC) achieving a complete response (CR) with initial BCG therapy. We evaluated the results of additional BCG therapy for TCC recurring after a CR to the initial treatment course of BCG.
MATERIALS AND METHODS
All of 129 patients treated with BCO with minimum follow-up of 2 years were reviewed to identify complete responders who subsequently recurred and received additional BCG therapy. The duration of initial response and the incidence and duration of a secondary CR were recorded.
RESULTS
Of 129 patients treated with BCG, 82 patients had a CR to the initial treatment of BCG. Sixteen of the 82 patients who had a CR to the initial treatment of BCG and had recurred were subsequently retreated with BCG. Ten of 16 patients receiving a second course of BCG achieved a second CR. Of 6 patients who had a second recurrence after second course of BCG, 2 received third course of BCG and 4 intravesical mitomycin-C therapy. One of 2 patients receiving a third course of BCG had a third CR and 1 proceeded to cystectomy for disease progression. Two of 4 patients receiving intravesical mitomycin-C therapy had a CR and 2 had a third recurrence. One of 2 patients who had a third recurrence received intravesical mitomycin-C therapy and 1 third course of BCG, then they achieved CR after therapy.
CONCLUSIONS
A repeat course of BCG is a reasonable option of therapy for transitional cell carcinoma that has recurred after a CR to a prior course of BCG. But careful monitoring by cytology, cystoscopy and biopsy is mandatory to continue disease free status after additional BCG.

2,279 View
13 Download

Methotrexate , Vinblastine , Doxorubicin and Cisplatin: Jin Soo Chung, Hyeon Hoe Kim, Chong Wook Lee; J Korean Cancer Assoc. 1994;26(4):618-626.

Abstract PDF: A study was performed to evaluated the effect of M-VAC(methotrexate, vinblastine, doxorubicin and cisplatin) chematheraty for advanced transitional cell carcinoma of the urinary tract. During July 1987 to June 1993, sixty eight patients with histologically proven advanced transitional cell carcinoma were treated with M-VAC chemotherapy at Seoul National University HospitaL Amang them, 43 patients with index lesions who received more than 2 cycles of chemotherapy, and were adequately followed up were analyzed for M-VAC chematherapy. Thirty nine patients were men and 4 women with the median age of 59 years. They were followed for 9 to 61 months with the median of 27 months after completion of chemotherapy. Of 43 eligible patients, complete remission was found in 9 patients(20.9%) and partial remis- sion in 1 l(25.6%), showing 46.5% of overa11 response rate. The overall median survival of the 43 patients were 14 months. In 9 patients with complete remission, the median duration of remis- sion was more than 20 months and median survival was more than 25 months with the two year survival rate of 100%. In 11 patients with partial remission, the median duration of remission was 11 months and median survival was 19 months with the one year survial rate of 81.8% and two year survival rate of 30%. The median survial of the 23 nonresponders was 10 months, with one and two year survival rate of 39.1% and 4.8%. Of the l4 patients with lymph node metastasis without any distant metastasis, 7 patients(50%) showed complete remission and another 3 patients(21.4%) showed partial remission, with the overall response rate of 72.4%. In con- trary, of the 29 patients with distant metastasis with or without nodal metastasis, the overall response rate was 34.5% including complete remission of only in 2 patients(6.9%). Toxicity was not negligible. Myelosuppression was observed in 58.1% of the patients, sepsis in 11.6/, renal toxicity in 48.8% and mucositis in 39.5%, but chemotherpy related death was not observed. M-VAC chemotherapy is apparently beneficial in patients with advanced transitional cell carcinoma of the urinary tract, especially with nodal metastasis, despite significant toxicity.

2,079 View
12 Download

Usefulness of MIB1 Expression as a Prognostic Factor in Transitional Cell Carcinoma of Urinary Bladder: Han Kyeum Kim, Young Sik Kim, In Sun Kim; J Korean Cancer Assoc. 1995;27(3):459-468.

Abstract PDF: Tumor proliferation is inversely associated with survival in patients with transitional cell carcinoma of urinary bladder. Ki67 and MIB1 monoclonal antibodies directed against different epitopes of the same proliferation-related antigen. Whereas Ki67 works only on frozen section, MIBl may be used also on fixed sections. In order to determine whether MIB1 is clinically a useful proliferation marker as well as prognostic one or not, MIB1 expresaion, in. bladder cancers were compared with conventional prognostic parameters such: as Ash histolbgic grade, and proliferation index including S-phase fraction calculated by flow cytometry. The expression of MIBI was assessed immunohistochemically in 36 cases of transitional cell carcinoma with anti-MIBl monoclonal antibody which can recognize a formai'in resistent epitope of Ki67 in formalin-fixed, paraffin wax embedded sections after incubation fn a microwave oven. Then, image analysis was employed for quantitation of immunostained MIBl expression. MIBI expression rates were highly correlated with Ash histologic grade. And, two pa- rameters revealed a good correlatian in linear regression analysis(Y = 4.16X - 3.01). Also, prolife- ration index and S-phase fraction calculated by flow cytometry were highly correlated with MIB1 expression(r=0.92, r=0.87, respectively) Therefore, MIB1 immunostaining is considered as a useful prognostic marker in transitional cell carcinoma of urinary bladder and a reason- able substitute for the Ki67 monoclonal antibody. In addition, the advantages of MIB1 immunostaining on paraffin sections include the feasibility of retrospective studies and of obtaining clear morphologic specimens that are optimal for use with computer-assisted image analysis systems.

2,730 View
12 Download

First
Prev
Page of 1
Next
Last

Search